This article is from the source 'rtcom' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at https://www.rt.com/news/523395-biontech-pfizer-vaccine-mutant-variants/
The article has changed 3 times. There is an RSS feed of changes available.
Version 1 | Version 2 |
---|---|
BioNTech says ‘no evidence’ it needs to change its Covid-19 jab formula despite new mutation variants | BioNTech says ‘no evidence’ it needs to change its Covid-19 jab formula despite new mutation variants |
(about 1 month later) | |
German pharmaceutical firm BioNTech has said there is no need to change its Covid-19 vaccine despite the increasing prevalence of new variants which carry mutations that may make current shots less effective. | German pharmaceutical firm BioNTech has said there is no need to change its Covid-19 vaccine despite the increasing prevalence of new variants which carry mutations that may make current shots less effective. |
In a quarterly financial results press release on Monday, BioNTech, who is working with Pfizer to deliver one of the world’s most-administered Covid-19 shots, said it was prepared to tweak its current vaccine formula but doesn’t think it needs to. | In a quarterly financial results press release on Monday, BioNTech, who is working with Pfizer to deliver one of the world’s most-administered Covid-19 shots, said it was prepared to tweak its current vaccine formula but doesn’t think it needs to. |
“To date, there is no evidence that an adaptation of BioNTech’s current Covid-19 vaccine against key identified emerging variants is necessary,” the statement read. The firm added it had developed a “comprehensive strategy to address these variants should the need arise in the future.” | “To date, there is no evidence that an adaptation of BioNTech’s current Covid-19 vaccine against key identified emerging variants is necessary,” the statement read. The firm added it had developed a “comprehensive strategy to address these variants should the need arise in the future.” |
BioNTech started tests in March on a “modified, variant-specific version” of its widely-used jab. “The aim of this study is to explore the regulatory pathway that BioNTech and Pfizer would pursue if SARS-CoV-2 were to change enough to require an updated vaccine,” it said. | BioNTech started tests in March on a “modified, variant-specific version” of its widely-used jab. “The aim of this study is to explore the regulatory pathway that BioNTech and Pfizer would pursue if SARS-CoV-2 were to change enough to require an updated vaccine,” it said. |
The firm said that multiple clinical trials of its Covid-19 vaccine are currently ongoing, including one on children from 6 months to 11 years of age, and that 450 million doses of its shot had been shipped to 91 countries around the world. | The firm said that multiple clinical trials of its Covid-19 vaccine are currently ongoing, including one on children from 6 months to 11 years of age, and that 450 million doses of its shot had been shipped to 91 countries around the world. |
BioNTech affirmed its expectation to reach manufacturing capacity of around three billion doses this year. | BioNTech affirmed its expectation to reach manufacturing capacity of around three billion doses this year. |
In the same statement, the firm announced its total revenues were estimated to be over €2 billion for the first quarter of 2021 – up from just €27.7 million for the three months ended March 31, 2020. | In the same statement, the firm announced its total revenues were estimated to be over €2 billion for the first quarter of 2021 – up from just €27.7 million for the three months ended March 31, 2020. |
If you like this story, share it with a friend! | If you like this story, share it with a friend! |